Skip to main content

Advertisement

Table 2 Number of patients, events, follow-up time, incidence rates, and hazard ratios for anuria in an IPTW cohort

From: Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study

Cohort Analysis Exposure group N Number of events Follow-up time (years) Incidence rate (per 100 person-years) Hazard ratio (95% CI)
      Mean ± SD Median   
Full cohort ITT ACEI/ARB 389 121 1.05 ± 0.89 0.81 29.6 0.86 (0.73, 1.02)
Non-user 497 159 0.87 ± 0.82 0.62 36.9  
Full cohort AT ACEI/ARB 389 53 0.35 ± 0.37 0.24   0.66 (0.51, 0.84)
Non-user 497 91 0.30 ± 0.33 0.19   
Baseline rGFR ≤20 ml/min ITT ACEI/ARB 379 118 1.05 ± 0.89 0.80   0.87 (0.74, 1.03)
Non-user 485 156 0.88 ± 0.82 0.62   
≥1 year on PD cohort ITT ACEI/ARB 203 59 0.93 ± 0.80a 0.71a   0.98 (0.76, 1.27)
Non-user 209 58 0.85 ± 0.78a 0.63a   
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-II receptor blocker, AT as treated, CI confidence interval, IPTW inverse probability of treatment weighted, ITT intention to treat, rGFR residual glomerular filtration rate, SD standard deviation
  2. aNote that follow-up for the ≥1 year on PD cohort began on day 365 of dialysis whereas in the other analyses follow-up began on day 90 of dialysis. Thus, patients in the ≥1 year on PD cohort were followed on average until day 690 of dialysis whereas patients in the unadjusted ITT analysis of the full cohort were followed on average until day 436 of dialysis